Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of$0.15. This compares to a loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. While Humacyte, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnin ...